首页> 外文期刊>Bioanalysis >Incurred sample reanalysis comparison of dried blood spots and plasma samples on the measurement of lopinavir in clinical samples
【24h】

Incurred sample reanalysis comparison of dried blood spots and plasma samples on the measurement of lopinavir in clinical samples

机译:干血斑和血浆样品在临床样品中洛匹那韦测定中的样品再分析比较

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Undoubtedly, incurred sample reanalysis (ISR) will become an integral part of regulated bioanalysis of dried blood spot (DBS) samples. In this article, we report results from an ISR study on DBS specimen and their corresponding plasma samples. Incurred samples were reanalyzed on their concentration of the antiretroviral drug lopinavir (LPV). Results: Bland-Altman comparison plots showed a high degree of agreement between the measurements; 94.7% of observed LPV concentrations were within bias ±2 SD. Moreover, 73.7% of obtained LPV concentrations from DBS ISR were in good compliance with general acceptance criteria (4-6-20 rule) on ISR testing, while plasma ISR failed on these acceptance criteria due to the low compliance of 10.5%. Conclusion: It was demonstrated that plasma ISR testing failed on acceptance criteria while corresponding incurred DBS specimens passed. Furthermore, the current article demonstrates that the stability of the antiretroviral drug LPV was significantly different in both biological matrices.
机译:背景:毫无疑问,发生的样品再分析(ISR)将成为干血斑(DBS)样品的受控生物分析的组成部分。在本文中,我们报告了对DBS标本及其相应血浆标本进行ISR研究的结果。重新分析所产生的样品的抗逆转录病毒药物洛匹那韦(LPV)的浓度。结果:Bland-Altman比较图显示测量之间的高度一致性; 94.7%的LPV浓度在偏差±2 SD之内。此外,从DBS ISR获得的LPV浓度的73.7%符合ISR测试中的通用验收标准(4-6-20规则),而血浆ISR由于这些标准的10.5%低而未通过这些验收标准。结论:证明血浆ISR测试未通过验收标准,而相应的DBS标本通过了。此外,当前的文章证明了抗逆转录病毒药物LPV的稳定性在两种生物基质中都存在显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号